TrialBMC medicine2025

Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial.

Xiao Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.